secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001171843-24-004649
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study
--------------------------------------------------------------------------------

- Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).
- Cash $2.0M; working capital $0.7M; received $300K post-quarter from Canadian govt SIF fund.
- EB05 (paridiprubart) chosen for HHS-funded ARDS platform study; Edesa supplies drug and tech support.
- Preparing IND for Phase 2 vitiligo study of anti-CXCL10 technology in moderate-to-severe patients.
- Q3 operating expenses $1.9M, down $0.2M YoY; R&D $0.9M, down $0.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184324004649/0001171843-24-004649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184324004649/f8k_080924.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer